Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetyltransferase 8 is an enzyme encoded by the NAT8 gene and is primarily expressed in the kidney and liver[1]. NAT8 resides in the endoplasmic reticulum, where it acts as a lysine N-acetyltransferase, catalyzing the N6-acetylation of lysine residues on various proteins using acetyl-CoA as a donor[1][2][5]. It also acetylates the free alpha-amino group of cysteine S-conjugates, contributing to the formation of mercapturic acids—important for the detoxification and excretion of reactive electrophiles[1][5]. NAT8 is implicated in the regulation of apoptosis and protein homeostasis (notably reticulophagy), and may also influence amyloid beta-peptide secretion through acetylation of BACE1 in neurons[1][5]. Mutations in NAT8 are associated with chronic kidney disease and rare syndromes such as Xia-Gibbs syndrome and iminoglycinuria[1][2].
Acetylation of lysine residues on proteins in the endoplasmic reticulum, Acetylation of cysteine S-conjugates to form mercapturic acids
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-acetyltransferase 8 (NAT8).